Key Takeaways
- Sesh says its PMTA covering 64 nicotine pouch SKUs has reached the Filing stage
- The application has entered substantive scientific review by the FDA
- Filing indicates “reviewability,” not compliance with the public health standard
- Imperial Brands’ Zone previously received an RTF due to deficiencies in bridging-related ingredient data
- Experts say the development signals regulatory divergence and has implications for market timing and investment risk
2Firsts
March24, 2026
Sesh Products US, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Premarket Tobacco Product Application (PMTA) and advanced it to the Filing stage. The application covers 64 SKUs.
The company said the application was submitted under Section 910(c)(1)(A)(i) of the Federal Food, Drug, and Cosmetic Act, seeking marketing authorization for new tobacco products. With the issuance of the acceptance letter, the application has entered the substantive scientific review phase of the PMTA process.
Sesh said the application covers its Sesh+ nicotine pouch series, including multiple flavors, nicotine strengths, and packaging configurations, intended for adult nicotine consumers aged 21 and over.
Regulatory Insight: From Completeness Review to Scientific Evaluation
Kurt Yang, Regulatory Expert at 2Firsts, said that passing the Filing stage marks a critical transition in the PMTA process, as the review shifts from assessing the completeness of the application to evaluating the accuracy and robustness of its scientific evidence.
“At this stage, the FDA has determined that the application contains a sufficiently complete and structured data package, allowing it to proceed to a full scientific review covering product characterization, toxicology, and population-level impact,” he said.
“However, this does not indicate that the product meets the public health standard, only that it is eligible to be evaluated against it.”
He noted that this stands in contrast to recent Refuse-to-File (RTF) decisions in the same category. In the case of Imperial Brands’ Zone nicotine pouch PMTAs, the FDA cited deficiencies in ingredient data used for bridging analyses, preventing the applications from entering substantive review.
“This highlights a fundamental distinction: applications that pass the Filing stage are considered scientifically reviewable, while those receiving RTF decisions are effectively excluded from the evaluation process due to gaps in foundational data.”
Market & Capital Perspective: Timing Window and Risk Re-rating
Echo Guo, Co-founder & COO of 2Firsts, said that Sesh’s progression to the Filing stage carries both market-timing and investment implications.
“From a market perspective, Sesh appears to be advancing shortly after the first wave of nicotine pouch applications—such as those from On! and ZYN—that have been closely watched as early regulatory benchmarks,” she said.
“This suggests the company remains within a relatively favorable window to compete, particularly as the category transitions from early regulatory uncertainty toward a more structured approval landscape.”
She noted that companies progressing earlier in the PMTA pipeline may gain advantages in brand positioning, retail access, and regulatory credibility.
“From an investment standpoint, reaching the Filing stage may prompt a partial re-rating of the company’s risk profile. It indicates that the application has passed an initial technical threshold, which could strengthen investor confidence in its regulatory execution capability.”
“However, this should be seen as a reduction in uncertainty rather than a validation of long-term value.”
The development underscores both progress and divergence in the nicotine pouch category, as some applications advance deeper into scientific review while others fail to meet the FDA’s filing threshold.
Cover Image:Screenshot of the Sesh official website homepage
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
